Document is current

Article History

Received: 22 December 2021

Accepted: 10 March 2022

First Online: 25 April 2022

Declarations

:

: The study protocol was reviewed and approved by the institutional review board of each participating institution. All patients provided written informed consent for this translational research. Some of the study results were presented in Poster session at the ESMO Virtual Congress 2021.

: Not applicable.

: TU: honoraria from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Astra Zeneca, Novartis Pharma K.K.; support for attending meetings from Eisai Co., Ltd.; consulting fees from Taiho, SK: personal fees from Astra Zeneca, personal fees from Pfizer, grants and personal fees from Boehringer Ingelheim, personal fees from Taiho, personal fees from Novartis, grants and personal fees from MSD, personal fees from Sumitomo Dainippon Pharma, grants and personal fees from Eisai, grants from Astellas, grants from Gilead Sciences, grants and personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Bristol-Myers Squibb, grants and personal fees from REGENERON, personal fees from Rakuten Medical, grants from PACT Pharma, grants from Takara Bio Inc., personal fees from GSK, grants and personal fees from Daiichi-Sankyo, grants and personal fees from Chugai , personal fees from ImmuniT Research Inc., grants from AMED (Japan Agency for Medical Research and Development), grants from JSPS (Japan Society for the Promotion of Science), and personal fees from PMDA (Pharmaceuticals and Medical Devices Agency), outside the submitted work, NM: grand from Chugai, Eli Lilly, Astra Zeneca, Pfizer, Daiichi-Sankyo, MSD, Eisai, Novartis, Sanofi, Kyowa-Kirin, and Nippon-Kayaku; honoraria from Chugai, Pfizer, Astra Zeneca, Eli Lilly, and Eisai; executive board and board of directors of JBCRG; TY: honoraria from Astra Zeneca, Daiichi-Sankyo, Eli Lilly, Novartis, Chugai, Eisai, Kyowa-Kirin, and Pfizer; SN: honoraria from Eli Lilly, Chugai, Pfizer, and Eisai; TN: honoraria from Chugai, Eli Lilly, Novartis, Astra Zeneca, Pfizer, Taiho, Daiichi-Sankyo, and Eisai; MT: honoraria from Astra Zeneca, Eli Lilly, Pfizer, Eisai, and Chugai; SS: grants from Taiho, Eisai, Chugai, Takeda, MSD, Novartis, Astra Zeneca, Daiichi Sankyo, and Eli Lilly; honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Nipponkayaku, data safety monitoring board or advisory board of Chugai/Roche, Astra Zeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, Novartis, executive board member of JBCRG, JBCS, BIG; KA: grants from Chugai Pharmaceutical, Eisai, and Takeda Pharmaceutical; honoraria from Chugai Pharmaceutical, Astra Zeneca, Novartis Pharma, Mochida Pharmaceutical, Eli Lilly, Eisai, Taiho Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical; KK: grants from TERUMO, Astellas, Eli Lilly, Kyoto Breast Cancer Research Network; consulting fees from Becton Dickinson Japan; honoraria from Eisai, Chugai, and Takeda; SM: grants from Nippon Boehringer Ingelheim, Eisai; honoraria from Astra Zeneca, Taiho Pharmaceutical Co. Ltd, Chugai Pharmaceutical, Nippon Boehringer Ingelheim, Bristol Myers Squibb Co. Ltd, Novartis Pharma KK, MSD KK, Kyowa Kirin Co. Ltd, Astellas Pharma, Pfizer Japan, Ono Pharmaceutical Co. Ltd, Eli Lilly Japan; SO: grant from Taiho, Eisai; honoraria from Astra Zeneca, Chugai, Eli Lilly, Taiho, Pfizer, Daiichi Sankyo; executive board member of JBCRG, JBCS; MT: grant from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG assoc., Eisai, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, and GL Science; honoraria from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis, Konica Minolta, Shimadzu, Yakult, and Nippon Kayaku; Advisory board of Kyowa-Kirin, Daiichi-Sankyo, Eli Lilly, Konica Minolta, BMS, Athenex Oncology, Bertis, Terumo, Kansai Medical Net; board of directors of JBCRG assoc., KBCRN, OOTR; associate editor of the British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, Cancer Science, Frontiers in Women’s Cancer, Asian Journal of Surgery, Asian Journal of Breast Surgery; deputy editor of International Journal of Oncology.